16-KDa prolactin and bromocriptine in postpartum cardiomyopathy

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 174-182

  Hilfiker Kleiner, Denise ^a   Struman, Ingrid ^a   Hoch, Melanie ^a   Podewski, Edith ^a,c   Sliwa, Karen ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Angiogenesis; Bromocriptine; Heart failure; Peripartum cardiomyopathy; Pregnancy; Prolactin; Therapy

Indexed keywords

BROMOCRIPTINE; CATHEPSIN D; PROLACTIN; HORMONE ANTAGONIST; PEPTIDE FRAGMENT; PROLACTIN 16 KDA FRAGMENT, HUMAN; PROLACTIN 16-KDA FRAGMENT, HUMAN;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HUMAN; HYPERPROLACTINEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT CARE; PERIPARTUM CARDIOMYOPATHY; PROTEIN DEGRADATION; PROTEIN SECRETION; THORAX RADIOGRAPHY; CARDIOMYOPATHY; FEMALE; METABOLISM; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PUERPERAL DISORDER; REVIEW;

BROMOCRIPTINE; CARDIOMYOPATHIES; FEMALE; HORMONE ANTAGONISTS; HUMANS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROLACTIN; PUERPERAL DISORDERS;

EID: 84871867733     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0095-7     Document Type: Article

References (75)

1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767-78. This position paper of the ESC study group of peripartum cardiomyopathy summarizes the current knowledge with regard to definition, etiology, and treatment of peripartum cardiomyopathy.
2. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183-8. (Pubitemid 30126607)
3. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368:687-93. (Pubitemid 44223695)
4. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302-4. (Pubitemid 47041992)
5. Fett JD. Peripartum cardiomyopathy. Insights from Haiti regarding a disease of unknown etiology. Minn Med. 2002;85:46-8.
6. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005; 80:1602-6.
7. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-97.
8. Duran N, Gunes H, Duran I, et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101:137-40.
9. Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441-6. (Pubitemid 43209169)
10. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A Cathepsin D-Cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589-600. (Pubitemid 46206082)
11. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465-73. This was the first small randomized trial in a PPCM patient collective in South Africa, and suggested a major beneficial effect of bromocriptine to improve recovery from PPCM.
12. Gonzalez C, Parra A, Ramirez-Peredo J, et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest. 2007;87:1009-17. (Pubitemid 47429188)
13. Tabruyn SP, Nguyen NQ, Cornet AM, et al. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol. 2005;19:1932-42. (Pubitemid 41007903)
14. Tabruyn SP, Sabatel C, Nguyen NQ, et al. The angiostatic 16 K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via NF-{kappa}B activation. Mol Endocrinol 2007.
15. Tabruyn SP, Sorlet CM, Rentier-Delrue F, et al. The antiangiogenic factor 16 K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol. 2003;17:1815-23. (Pubitemid 37072297)
16. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;44:964-8.
17. Selle T, Renger I, Labidi S, et al. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol. 2009; 5:175-89.
18. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15:645-50.
19. Tibazarwa K, Lee G, Mayosi B, et al. The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr. 2012;23:1-8.
20. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFNgamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10:861-8.
21. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53:1475-87.
22. Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance: a powerful diagnostic and prognostic tool in modern cardiology. Prog Cardiovasc Dis. 2011;54:179-80.
23. Leurent G, Baruteau AE, Larralde A, et al. Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis. Int J Cardiol. 2009;132:e91-3.
24. Kawano H, Tsuneto A, Koide Y, et al. Magnetic resonance imaging in a patient with peripartum cardiomyopathy. Intern Med. 2008;47:97-102. (Pubitemid 351377310)
25. Mouquet F, Lions C, de Groote P, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol. 2008;18:2765-9.
26. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J. 1995;129:421-2.
27. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med. 1963;111:651-5.
28. Meyer GP, Labidi S, Podewski E, et al. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J Med Case Rep. 2010;4:80.
29. Fett JD, Sundstrom BJ, Etta King M, Ansari AA. Mother-daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86:331-2.
30. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121:2169-75.
31. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-Associated or peripartum cardiomyopathy. Circulation. 2010;121:2176-82.
32. Bahl A, Swamy A, Sharma Y, Kumar N. Isolated noncompaction of left ventricle presenting as peripartum cardiomyopathy. Int J Cardiol. 2006;109:422-3.
33. Lea B, Bailey AL, Wiisanen ME, et al. Left ventricular noncompaction presenting as peripartum cardiomyopathy. Int J Cardiol. 2012;154:e65-6.
34. Rehfeldt KH, Pulido JN, Mauermann WJ, Click RL. Left ventricular hypertrabeculation/noncompaction in a patient with peripartum cardiomyopathy. Int J Cardiol. 2010;139:e18-20.
35. Paterick TE, Gerber TC, Pradhan SR, et al. Left ventricular noncompaction cardiomyopathy: what do we know? Rev Cardiovasc Med. 2010;11:92-9.
36. Frischknecht BS, Attenhofer Jost CH, Oechslin EN, et al. Validation of noncompaction criteria in dilated cardiomyopathy, and valvular and hypertensive heart disease. J Am Soc Echocardiogr. 2005;18:865-72. (Pubitemid 41111569)
37. Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation. 1990;82:507-13.
38. Stollberger C, Finsterer J. Trabeculation and left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr. 2004;17:1120-1. aothor reply 1121.
39. Probst S, Oechslin E, Schuler P, et al. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. Circ Cardiovasc Genet. 2011;4:367-74.
40. Hoedemaekers YM, Caliskan K, Michels M, et al. The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy. Circ Cardiovasc Genet. 2010;3:232-9.
41. Walenta K, Schwarz V, Schirmer SH, et al. Circulatingmicroparticles as indicators of peripartum cardiomyopathy. Eur Heart J 2012.
42. Leanos-Miranda A, Marquez-Acosta J, Cardenas-Mondragon GM, et al. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab. 2008;93:2492-9. (Pubitemid 352008512)
43. Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011;57:85-93.
44. Lkhider M, Castino R, Bouguyon E, et al. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J Cell Sci. 2004; 117:5155-64. (Pubitemid 39517530)
45. Ferrara N, Clapp C, Weiner R. The 16 K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology. 1991; 129:896-900.
46. Piwnica D, Touraine P, Struman I, et al. Cathepsin D processes human prolactin into multiple 16 K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol. 2004;18:2522-42. (Pubitemid 39335986)
47. Clapp C,Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology. 1992;130:1380-6.
48. D'Angelo G, Martini JF, Iiri T, et al. 16 K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol. 1999;13:692-704. (Pubitemid 30645323)
49. Lee SH, Kunz J, Lin SH, Yu-Lee LY. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1- Rac1-Pak1 signaling pathway. Cancer Res. 2007;67:11045-53. (Pubitemid 350145935)
50. Gonzalez C, Corbacho AM, Eiserich JP, et al. 16 K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology. 2004;145:5714-22. (Pubitemid 39564613)
51. Nguyen NQ, Cornet A, Blacher S, et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16 K hPRL. Mol Ther. 2007;15:2094-100. (Pubitemid 350148924)
52. Kinet V, Castermans K, Herkenne S, et al. The angiostatic protein 16 K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells. Endocrinology. 2011;152:4062-71.
53. Kinet V, Nguyen NQ, Sabatel C, et al. Antiangiogenic liposomal gene therapy with 16 K human prolactin efficiently reduces tumor growth. Cancer Lett. 2009;284:222-8. This study describes potential beneficial effects of 16-kDa prolactin in the treatment of cancer.
54. Pan H, Nguyen NQ, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16 K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2004;45:2413-9. (Pubitemid 38902617)
55. Duenas Z, Rivera JC, Quiroz-Mercado H, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci. 2004;45:2049-55. (Pubitemid 38902570)
56. Garcia C, Aranda J, Arnold E, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest. 2008;118:2291-300. (Pubitemid 351872346)
57. Habedank D, Kuhnle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008.
58. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol. 2007;50:2354-5. (Pubitemid 350192108)
59. Reuwer AQ, Reuwer PJ, van der Post JA, et al. Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia. Med Hypotheses. 2010;74:348-52.
60. Macotela Y, Aguilar MB, Guzman-Morales J, et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci. 2006;119:1790-800. (Pubitemid 43811005)
61. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010; 12:1048-57.
62. Kochenour NK. Lactation suppression. Clin Obstet Gynecol. 1980;23:1045-59. (Pubitemid 11181720)
63. Hopp L, Haider B, Iffy L. Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement. Int J Cardiol. 1996;57:227-32. (Pubitemid 27037390)
64. Y-Hassan S, Jernberg T. Bromocriptine-induced coronary spasm caused acute coronary syndrome, which triggered its own clinical twin-Takotsubo syndrome. Cardiology. 2011;119:1-6.
65. Khurana S, Liby K, Buckley AR, Ben-Jonathan N. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16 K fragment by thrombin. Endocrinology. 1999;140:4127-32. (Pubitemid 30647110)
66. James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol. 2005;3:187-97. (Pubitemid 41387381)
67. Goland S, Schwarz ER, Siegel RJ, Czer LS. Pregnancy-Associated spontaneous coronary artery dissection. Am J Obstet Gynecol. 2007;197:e11-3. (Pubitemid 350166264)
68. Patti G, Nasso G, D'Ambrosio A, et al. Myocardial infarction during pregnancy and postpartum: a review. G Ital Cardiol. 1999;29:333-8. (Pubitemid 29177385)
69. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008;52:171-80. (Pubitemid 351927266)
70. Bolyakov A, Paduch DA. Prolactin in men's health and disease. Curr Opin Urol. 2011;21:527-34.
71. Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 2010;73:502-7.
72. Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 4:S44-53.
73. Martinez-Martin P, Kurtis MM. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism Relat Disord. 2009;15 Suppl 4:S58-64.
74. Valiquette G. Bromocriptine for diabetes mellitus type II. Cardiol Rev. 2011;19:272-5. This study emphasizes positive effects of bromocriptine treatment in patients with diabetes mellitus type II.
75. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503-8.